Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
NEW YORK, March 08, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 38th Annual Health Care Conference in Boston, MA. The presentation is scheduled for Tuesday, March 13, 2018 at 9:20 am ET.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.
CONTACT:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations
646-440-9370
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
[email protected]
212-213-0006
